Covid-19 roundup: Mod­er­na notes high­er my­ocardi­tis risk for young males when com­pared to Pfiz­er's vac­cine; EMA signs off on Roche, Cell­tri­on mAb treat­ments

Mod­er­na’s new CMO Paul Bur­ton spoke to re­porters Thurs­day morn­ing, at­tempt­ing to de­fend his com­pa­ny’s vac­cine against ques­tions around heart-re­lat­ed risks that ap­pear to be crop­ping up in very rare in­stances among younger men.

The me­dia push comes as the Mod­er­na vac­cine has proven to be over­whelm­ing­ly safe in more than 155 mil­lion in­di­vid­u­als. But coun­tries like Fin­land, Swe­den, Nor­way and Den­mark have lim­it­ed use of the Mod­er­na vac­cine to men over the age of 30, as it found the younger men who re­ceived the vac­cine, known as Spike­vax, had a slight­ly high­er risk of de­vel­op­ing my­ocardi­tis when com­pared to oth­er vac­cines.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER